ArticleVeterinary medicine and science2025
Retrospective Analysis of Clinical Presentation, Prognostic Factors and Outcome in 32 Dogs with Subcutaneous Mast Cell Tumours Treated with a Curative-Intent Approach.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubcutaneous mast cell tumours (ScMCTs) have been traditionally associated with a good prognosis, with low rates of recurrence and metastasis.
objectivesThis study aims to describe the clinical presentation, outcome, and prognostic factors in dogs diagnosed with ScMCTs and treated with a curative-intent approach.
methodsClinical and histopathological data were retrospectively collected from dogs diagnosed with ScMCTs after undergoing curative-intent surgery and complete staging between 2018 and 2023 in a single institution. Adjuvant and neoadjuvant therapies were allowed. The study's endpoints were the disease-free interval (DFI) and disease-specific survival time (DSST). Variables, including location, histopathological description, clinical stage, infiltrative behaviour, atypia, Darier's sign, surgical margins, mitotic count (MC) >4 in 10 high power fields (HPF), nodal status, and chemotherapy after surgery, were evaluated as potential influences on DFI and DSST.
resultsThirty-two cases were included. Lymphadenectomies were performed in 18/32 (56.3%), and nodal metastases (early or overt) were documented in 12/32 (37.5%). The median follow-up was 405 days (range 79-1312). In 9/32 (28.1%), the disease progressed, and 7/32 (21.9%) died of ScMCT-related causes. The median DFI and DSST were not reached at 1312 days. The overall 1-year and 2-year survival rates were 80% and 70%, respectively. Patients presenting with Darier's sign, MC >4 in 10 HPF, and those who received chemotherapy had a higher risk of dying from the disease (hazard ratios of 14.9, 5.8 and 8.4, respectively).
conclusionsOur results suggest that despite the overall good long-term prognosis of ScMCTs, they may exhibit a higher metastatic rate at presentation than previously reported. Additionally, patients with Darier's sign or a high mitotic count may be associated with a poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.